Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 18/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL602692 | 0.90 | GPBAR1 (0.42) | GPBAR1NR1H4 | |
| SCHEMBL10228092 | 0.83 | KDM4E (0.33) | GPBAR1 | |
| SCHEMBL10277264 | 0.80 | GPBAR1 (0.60) | GPBAR1NR1H4 | |
| SCHEMBL14863454 | 0.79 | GPBAR1 (0.45) | GPBAR1NR1H4 | |
| SCHEMBL15587773 | 0.79 | GPBAR1 (0.58) | GPBAR1NR1H4 | |
| SCHEMBL15527782 | 0.77 | GPBAR1 (0.50) | GPBAR1NR1H4 | |
| SCHEMBL603676 | 0.77 | ADAM17 (0.47) | GPBAR1NR1H4 | |
| SCHEMBL15528001 | 0.76 | GPBAR1 (0.56) | GPBAR1NR1H4 | |
| SCHEMBL15527875 | 0.75 | GPBAR1 (0.55) | GPBAR1NR1H4 | |
| SCHEMBL13259093 | 0.74 | KCNH2 (0.35) | GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785488-B2 | Triazole and imidazole derivatives for use as TGR5 agonists in the treatment of diabetes and obesity | EXELIXIS PATENT COMPANY LLC (US) | 2014-07-22 | — | — | US | disclosed |
| WO-2013164838-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF DIABETES, OBESITY OR RELATED DISORDERS | CADILA HEALTHCARE LIMITED (IN) | 2013-11-07 | — | — | WO | disclosed |
| WO-2013164838-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF DIABETES, OBESITY OR RELATED DISORDERS | CADILA HEALTHCARE LIMITED (IN) | 2013-11-07 | — | — | WO | disclosed |
| US-20120040985-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | EXELIXIS PATENT COMPANY LLC (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2010093845-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | EXELIXIS, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20080241102-A1 | Polymeric Prodrug with a Self-Immolative Linker | COMPLEX BIOSYSTEMS GMBH (DE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040985-A1 | TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY | GPR119, GLP1R, GCGR | GPBAR1 8/4885NR1H4 53/4885NFE2L2 2710/4885 |
| US-20080241102-A1 | Polymeric Prodrug with a Self-Immolative Linker | PAICS, MPI, TYMP | GPBAR1 1975/4885NR1H4 2004/4885NFE2L2 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.